Simone Rizzetto @SimoneRizzetto88: "📊 PORTFOLIO UPDATE: Biotech Surge,..."

Italy

📊 PORTFOLIO UPDATE: Biotech Surge, Memory Crisis, and Hawkish Hangover 🚀 One week since the last update and the momentum in biotech has been remarkable. The FDA advisory committee's unanimous vote on Moderna's flu vaccine set the tone, while the broader semiconductor sector grappled with a memory supply crunch. Portfolio performing well above the market and with less volatility. YTD +11.93%, MTD +1.58%. 📌 Biotech: FDA Momentum and Catalysts ➤ $MRNA (Moderna Inc): Following last week's unanimous 9-0 FDA advisory committee vote, Moderna held its Science Day showcasing an expanding pipeline across oncology and rare disease. The stock surged 14% to a new 52-week high of $69.29, up 130% YTD. Wall Street remains cautious with consensus at $43.45 versus current ~$67. The key date is August 5, the PDUFA decision on flu vaccine approval. ➤ $HIMS (Hims & Hers Health Inc): The GLP-1 telehealth story gained more steam. Eucalyptus acquisition completed, expanding to UK, Australia and Canada. CEO teased wearable integration. With the FDA peptide advisory meeting July 23-24 potentially unlocking a new product category, Barron's estimates HIMS could capture $440M of the $2.2B peptides market. My position continue growing. ➤ $GH (Guardant Health Inc): Multiple analyst upgrades this period, Barclays at $150, RBC Capital at $185, Mizuho at $175. Stock hit a new 52-week high as Guardant360 Liquid CDx received expanded FDA approval and Shield entered ACS screening guidelines. Revenue guidance of $1.25-$1.28B signals 27-30% growth. ➤ $CRSP (CRISPR Therapeutics AG): Needham reiterated Buy with $82 PT citing H2 2026 data catalysts. Volume spiked to 198% above average on June 26, suggesting institutional accumulation. Cathie Wood pivoting ARKK from tech to biotech, with CRSP as the third largest holding. 📌 Pharma: Pipeline Milestones ➤ $GSK.L (GlaxoSmithKline): Mixed week. J.P. Morgan and Barclays maintain Sell ratings, but Dodge & Cox lifted its stake to 5.01% on June 26. The $10.6B Nuvalent tender offer adds three lung cancer products. Q2 earnings July 28 will be key. ➤ $ROP.ZU (Roche Holding Ltd): Roche launched the AXELIOS 1 sequencing platform on June 29 with same-day whole-genome sequencing. FDA accepted the Lunsumio VELO plus Polivy sBLA showing 59% risk reduction in lymphoma. H2 results on July 23. 🚀 Tech: Memory Crisis ➤ $AMD (Advanced Micro Devices Inc): AMD acquired MEXT on June 28, an AI memory optimization startup cutting DRAM costs nearly in half for enterprise AI workloads. Micron reported Q3 revenue up 346%, confirming memory shortage through 2028. Bernstein maintains $600 PT. I significantly cut AMD in the past weeks. ➤ $AAPL (Apple): Facing the memory crunch too. MacBook and iPad prices raised on June 25 due to DRAM costs up 98%, sending the stock down roughly 5%. iPhone 18 price hikes now expected before fall launch. BofA maintains Buy at $380. 📌 My Stance Biotech is having a moment. Between FDA endorsements, analyst upgrades, and catalysts loading for H2 2026, the risk-reward in selective names remains compelling. Moderna's August PDUFA date and HIMS' July peptide meeting are catalysts I'm watching closely. Although companies are stating that memory shortage is structural and will continue for years, I am not onboard. I believe software-side optimization of LLM will eventually drag ram prices down very fast. $SPX500 $NSDQ100

Not investment advice. The author may have financial interests in the mentioned instruments.